Study indicates best method for transplanting neural stem into spinal cord injury sit
Study indicates best method for transplanting neural stem into spinal cord injury site
Wednesday - Jul 13, 2011, 04:05am (GMT+5.5)
Washington - A study of optimal routes for transplanting neural stem/progenitor cells (NS/PCs) in animal models of spinal cord injury (SCI) has demonstrated that intralesional (IL) injection conferred benefits over intravenous injection (IV) and intrathecal (IT) injection.
The study has been carried by team of Keio University (Japan) researchers.
"Spinal cord injury usually results in severe, paralytic damage because the adult central nervous system has little potential for regeneration after injury," said corresponding author Dr. Masaya Nakamura of the Keio University School of Medicine's Department of Orthopedic Surgery.
"With cell transplantation of neural stem/progenitor cells being a promising strategy, our study sought to determine the best method of application for optimal cell survival and subject safety,” added Nakamura.
Kessler is the First Rehabilitation Center in the Nation to Use New Robotic Gait Trai
Kessler is the First Rehabilitation Center in the Nation to Use New Robotic Gait Training System
WEST ORANGE, N.J., July 13, 2011 /PRNewswire/ -- Kessler Foundation (www.kesslerfoundation.org) and Kessler Institute for Rehabilitation (www.kessler-rehab.com) are the first rehabilitation centers in the U.S. to implement the new LokomatPro V6, an advanced robotic training system designed to improve mobility in individuals with spinal cord injury, brain injury, stroke, multiple sclerosis or other neurological diseases. This new system, developed by Hocoma (http://www.hocoma.com/en/), a Swiss-based manufacturer, offers appropriate patients an intensive program of activity-based therapy that has been shown to improve overall function, movement and walking.
"Robotic therapy is a new frontier in the treatment of individuals with spinal cord injury, stroke and other conditions that result in motor deficits," explained Steven Kirshblum, M.D., Medical Director and Director of Spinal Cord Injury Services at Kessler Institute for Rehabilitation (http://bit.ly/oOi1Ek). "The Lokomat is one device that is helping to take locomotor training to a new level. This new system will offer patients greater range of motion, variable speeds and augmented feedback, which allows users to visualize themselves walking in a variety of environments, all of which can contribute to greater functional gains. In addition, we will be studying its role in helping to prevent secondary complications of paralysis by improving strength, mobility, respiratory and bladder function, circulation and bone density."
Cleveland researchers use experimental nerve 'bridge' to restore breathing in rats with spinal cord injuries (video)
Published: Wednesday, July 13, 2011, 1:00 PM Updated: Wednesday, July 13, 2011, 3:29 PM
By John Mangels, The Plain Dealer The Plain Dealer
CLEVELAND, Ohio -- Using tools familiar to any gardener -- a chemical fertilizer and a sort of high-tech trellis -- Cleveland researchers have coaxed skittish nerve fibers to bridge a gap in rats' damaged spinal cords and forge new connections.
The repairs, though experimental, revived the rats' partially paralyzed diaphragm muscles, restoring normal or near-normal breathing in nine of 11 test animals, the Case Western Reserve University scientists report Thursday in the journal Nature.
"It's pretty amazing," said CWRU neuroscientist Jerry Silver, who led the research project and described it as the culmination of 30 years of effort. "Our work is one of the most convincing demonstrations [to date] of the return of robust function" after paralysis.
The CWRU approach blends two nerve-regrowth methods, leveraging the power of each.
"The experiments are significant in demonstrating that this combination of two repair strategies can work together to enhance recovery in the complex circuitry that controls breathing," spinal cord injury researcher James Fawcett, who heads Britain's Cambridge Centre for Brain Repair at the University of Cambridge, said via email. "This paper from the Silver laboratory shows that a combination treatment can be very successful." Fawcett was not involved in the CWRU project.
Researchers have tried many techniques over the years to overcome the devastation of spinal cord injuries, which affect 12,000 Americans annually. Progress has been slow, a testament to the human nervous system's complexity.
Much of that experimental work has focused on re-establishing the ability to walk, a goal that remains unmet. Silver's lab has concentrated instead on the challenges of regaining breathing and bladder control. "Our goal was to target one critical muscle that [paralyzed] people would like back," he said.
Those two bodily functions are far less complicated than walking in terms of making neurological fixes. The shortest stroll requires a suite of highly coordinated limb and trunk movements involving dozens of muscles; by contrast, breathing and urination basically involve flexing only the diaphragm or the sphincter. Restoring them could boost paralyzed patients' long-term survival and dramatically improve their day-to-day lives.
Rutgers defensive lineman Eric LeGrand Wednesday tweeted photos of himself standing up for the first time since suffering a spinal cord injury that left him paralyzed nine months ago.
With his mother at his side, LeGrand tweeted a picture of himself standing with assistance, telling his 7,000-plus followers, "Standing up little by little in therapy."
Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Paten
Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
July 14, 2011 8:02 AM EDT
ROCKVILLE, Md., July 14, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth." The patents cover three new compounds and include both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo.
Neuralstem's first neurogenic patented compound is currently in a Phase I FDA-approved safety trial in major depressive disorder. The Phase Ia trial, which is in healthy volunteers, is scheduled to be completed in August. The Phase Ib safety trial in depressed patients is expected to commence this fall
Congratulations, Dee Manouli. You provide a valuable research and news service for CareCure.
I have to say though I miss seeing the article headline as a new subject line each time you post a fresh article. Some of the article titles really draw me in. Just saying... Keep up the awesome work.
Comment